Biohaven Pharmaceutical (BHVN) set to announce results on Friday

Biohaven Pharmaceutical (NYSE:BHVN) is expected to release earnings data before market open on Friday, February 25. Analysts expect Biohaven Pharmaceutical to post earnings of ($2.07) per share for the quarter. Those interested in participating in the company’s earnings conference call can do so using this link.

BHVN shares opened at $140.94 on Friday. Biohaven Pharmaceutical has a 12-month low of $62.57 and a 12-month high of $151.51. The stock has a market capitalization of $9.23 billion, a P/E ratio of -10.30 and a beta of 1.04. The company’s 50-day moving average is $127.62 and its 200-day moving average is $127.64.

Several analysts have released reports on BHVN shares. Mizuho raised his price target on Biohaven Pharmaceutical shares from $135.00 to $144.00 and gave the stock a “buy” rating in a Thursday, November 18 research note. Morgan Stanley raised its price target on shares of Biohaven Pharmaceutical from $145.00 to $148.00 and gave the stock an “equal weight” rating in a Friday, Jan. 7 research note. Cantor Fitzgerald raised his price target on Biohaven Pharmaceutical shares from $165.00 to $177.00 and gave the stock an “overweight” rating in a Wednesday, November 10 research note. UBS Group raised its target price on Biohaven Pharmaceutical shares from $150.00 to $160.00 in a Tuesday, January 4, research note. Finally, HC Wainwright reiterated a “buy” rating and issued a target price of $160.00 on Biohaven Pharmaceutical shares in a research note on Friday, January 7. Three analysts gave the stock a hold rating and eight gave the company a buy rating. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $147.55.

(A d)

Helium is quickly becoming one of the most valuable resources on the planet. It’s already soared 160% in the past few years…and investors say that’s just the beginning. This is why investors call the land recently discovered by this company: “Saudi Arabia of helium”.

In related news, the director Declan Doogan sold 24,525 shares in a trade on Monday, November 29. The shares were sold at an average price of $112.80, for a total transaction of $2,766,420.00. The transaction was disclosed in a document filed with the SEC, accessible via this link. Also, CAD George C. Clark sold 9,375 shares in a trade on Wednesday, January 19. The shares were sold at an average price of $117.01, for a total transaction of $1,096,968.75. Disclosure of this sale can be found here. Insiders sold a total of 104,734 shares of the company worth $11,502,028 over the past three months. Insiders hold 15.20% of the shares of the company.

Several hedge funds have recently increased or reduced their stake in BHVN. Morgan Stanley increased its holdings of Biohaven Pharmaceutical shares by 30.6% during the 2nd quarter. Morgan Stanley now owns 53,669 shares of the company valued at $5,210,000 after buying an additional 12,560 shares in the last quarter. LPL Financial LLC bought a new position in shares of Biohaven Pharmaceutical during Q3 at a value of $462,000. UBS Group AG increased its stake in Biohaven Pharmaceutical by 33.2% in the third quarter. UBS Group AG now owns 6,045 shares in the company worth $839,000 after acquiring an additional 1,506 shares in the last quarter. The Canada Pension Plan Investment Board acquired a new stake in Biohaven Pharmaceutical in the 4th quarter at a value of $104,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in Biohaven Pharmaceutical in the 4th quarter at a value of $640,000. 89.17% of the shares are currently held by institutional investors.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Co Ltd. is a clinical-stage biopharmaceutical company, dedicated to the research and development of late-stage product candidates targeting neurological diseases, including rare diseases. It is focused on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-linked peptide receptor antagonists and glutamate modulators.

See also

Earnings history of Biohaven Pharmaceutical (NYSE: BHVN)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Biohaven Pharmaceutical right now?

Before you consider Biohaven Pharmaceutical, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Biohaven Pharmaceutical didn’t make the list.

Although Biohaven Pharmaceutical currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here